Trisenox® in Women With Metastatic Endometrial Cancer
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to see whether women who have already received
chemotherapy for their endometrial cancer, or who have disease that has spread outside of the
uterus, will respond to the drug arsenic trioxide (Trisenox®) as judged by shrinkage of their
tumor.